US 12,275,780 B2
Monoclonal antibodies against Ambra-1
Penny Lovat, Newcastle Upon Tyne (GB); Marie Labus, Newcastle Upon Tyne (GB); Rob Ellis, Newcastle Upon Tyne (GB); and Ashleigh McConnell, Newcastle Upon Tyne (GB)
Assigned to AMLO Biosciences Limited, Newcastle Upon Tyne (GB)
Appl. No. 17/309,218
Filed by AMLO Biosciences Limited, Newcastle Upon Tyne (GB)
PCT Filed Nov. 4, 2019, PCT No. PCT/GB2019/053120
§ 371(c)(1), (2) Date May 7, 2021,
PCT Pub. No. WO2020/099828, PCT Pub. Date May 22, 2020.
Claims priority of application No. 1818618 (GB), filed on Nov. 15, 2018; and application No. 1911211 (GB), filed on Aug. 6, 2019.
Prior Publication US 2021/0324059 A1, Oct. 21, 2021
Int. Cl. C07K 16/18 (2006.01); A61K 45/06 (2006.01); G01N 33/574 (2006.01)
CPC C07K 16/18 (2013.01) [A61K 45/06 (2013.01); G01N 33/5743 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); G01N 2333/4703 (2013.01); G01N 2800/52 (2013.01)] 16 Claims
 
1. An in vitro assay for predicting an increased risk of metastasis in a subject suffering from melanoma, the assay comprising:
contacting a tissue sample obtained from the subject with an antibody against Ambra-1, wherein the antibody against Ambra-1 comprises the following heavy chain variable domain complementarity determining regions (CDRs):
(a) HCDR1 comprising the amino acid sequence of SEQ ID NO:1;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:2; and
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:3; and
wherein the antibody against Ambra-1 comprises the following light chain variable domain complementarity determining regions (CDRs):
(a) LCDR1 comprising the amino acid sequence of SEQ ID NO:4;
(b) LCDR2 comprising the amino acid sequence of SEQ ID NO:5; and
(c) LCDR3 comprising the amino acid sequence of SEQ ID NO:6,
wherein the tissue sample comprises tissue overlying a primary melanoma and the presence of Ambra-1 creates an Ambra-1-antibody complex; and
detecting and/or quantifying the Ambra-1-antibody complex, wherein optionally:
(a) the tissue sample comprises keratinocytes overlying the primary melanoma and the Ambra-1-antibody complex is detected in the keratinocytes; and/or
(b) the Ambra-1-antibody complex is detected and/or quantified by visual assessment or by an automated slide scanner.